{"drugs":["Carticel","Chondrocytes, Autologous Cultured"],"mono":{"0":{"id":"925294-s-0","title":"Generic Names","mono":"Chondrocytes, Autologous Cultured"},"1":{"id":"925294-s-1","title":"Dosing and Indications","sub":{"0":{"id":"925294-s-1-4","title":"Adult Dosing","mono":"<ul><li>The cell therapy product that consists of autologous cultured human cartilage cells expanded ex vivo and provided in ChondroCelect implantation suspension has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li><b>Autologous chondrocyte implantation - Defect of articular cartilage, Femoral condyle of the knee:<\/b> 0.8 to 1 million cells\/cm(2) (80 to 100 mcL of product\/cm(2) of defect) INTRA-ARTICULARLY implanted (European Medicines Agency-approved dosing)<\/li><\/ul>"},"1":{"id":"925294-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy not established in pediatric patients younger than 18 years "},"3":{"id":"925294-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Autologous chondrocyte implantation - Defect of articular cartilage, Femoral condyle of the knee<br\/>"}}},"3":{"id":"925294-s-3","title":"Contraindications\/Warnings","sub":[{"id":"925294-s-3-9","title":"Contraindications","mono":"<ul><li>advanced osteoarthritis of the knee<\/li><li>a femoral epiphyseal growth plate that is not fully closed<\/li><li>hypersensitivity to Dulbecco's Modified Eagles Medium (DMEM), bovine serum, or any component of the product<\/li><\/ul>"},{"id":"925294-s-3-10","title":"Precautions","mono":"<ul><li>Musculoskeletal:<\/li><li>-- acute or recent history of bone or joint infections; delay therapy until recovery<\/li><li>-- knee problems, including early osteoarthritis, osteochondritis dissecans, instability of the knee, cartilage lesions at locations other than the femoral condyle, lesions of knee ligaments or of the meniscus, varus or valgus malalignment, and inflammatory joint disease; correct prior to autologous cell repair or during implantation at the latest<\/li><li>Other:<\/li><li>-- autologous use only; do not administer to other patients<\/li><li>-- BMI over 30 may compromise grafting success; use generally not recommended<\/li><li>-- early or vigorous activity may compromise grafting and durability of cartilage repair or cause graft failure; follow rehabilitation instructions carefully<\/li><li>-- during rehabilitation period, driving cars and using machines may be limited<\/li><li>-- use of fibrin glue inside the cartilage defect bed is not recommended<\/li><\/ul>"},{"id":"925294-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"925294-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"925294-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Musculoskeletal:<\/b>Arthralgia (47.1%), Cartilage disorder, Hypertrophy (27.4%), Joint crepitus (17.6%), Joint swelling (13.7%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Deep venous thrombosis (1% to less than 10%)<\/li><li><b>Neurologic:<\/b>Transient ischemic attack (0.1% to less than 1%)<\/li><li><b>Respiratory:<\/b>Pulmonary embolism (0.1% to less than 1%)<\/li><li><b>Other:<\/b>Complication of surgical procedure, Delamination (1% to less than 10%), Failure, Treatment failure (1% to less than 10%)<\/li><\/ul>"},"6":{"id":"925294-s-6","title":"Drug Name Info","sub":{"0":{"id":"925294-s-6-17","title":"US Trade Names","mono":"Carticel<br\/>"},"2":{"id":"925294-s-6-19","title":"Class","mono":"Musculoskeletal Agent<br\/>"},"3":{"id":"925294-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"925294-s-9","title":"Administration","mono":"<b>Implantation<\/b><br\/><ul><li>Each vial contains 4 million autologous cultured human cartilage cells in 0.4 mL of suspension (10,000 cells\/mcL), sufficient to treat predefined lesion size measured at biopsy procurement.<\/li><li>Store between 15 and 25 degrees C; do not refrigerate or freeze.<\/li><li>Resuspend by gently tapping the vial to prior to administration.<\/li><li>Match patient name to the donor identification on the shipment documentation and product vial prior to implantation.<\/li><li> Prior to administration, debride defect bed and provide complete joint hemostasis to ensure secure implantation.<\/li><li>Administer during arthrotomy, ensuring direct contact of the implanted cells with the defect bed; seal with a biological membrane to secure the implant<\/li><li>If using the cell-seeding method, ensure direct contact of implanted cells with the defect bed by using stitches on the edge of the collagen membrane; use of only fibrin glue is not recommended.<\/li><\/ul>"}}}